Dr. Qing Zhu to become China R&D Head, Dr. Ankang Li to join the Board, Mr. Rico Liang to become China GM, and Mr. Yongqing (Rogers) Luo resigned from the Board and his current positions

DURHAM, N.C., United States and BEIJING, China - September 2, 2022 - Brii Biosciences Limited (“Brii Bio” or the “Company”, stock code: 2137.HK), a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public health burdens, today announced that Qing Zhu, Ph.D., Senior Vice President and Head of Biopharma of Brii Bio, will relocate to Beijing, China, and become Head of China R&D. Mr. Yongqing (Rogers) Luo has resigned from his current position as Executive Director, President, and Greater China General Manager of Brii Bio, and Chief Executive Officer of TSB Therapeutics, a subsidiary of Brii Bio, effective from September 15, 2022. Ankang Li, Ph.D., J.D., CFA, Chief Financial and Strategy Officer of Brii Bio, will join the Board to serve as an Executive Director on September 30, 2022, and become Chief Executive Officer of TSB Therapeutics, effective from September 16, 2022. Mr. Rico Liang, Vice President of Scientific and Medical Affairs of Brii Bio, will become Senior Vice President and Greater China General Manager on September 16, 2022.

“In China, Brii Bio focuses on developing functional cure for chronic hepatitis B (“HBV”) and antibiotics against multi-drug resistant bacteria. We have recently initiated or will soon initiate multiple key clinical studies in China and Asia Pacific region. We are glad that our experienced R&D leader, Dr. Qing Zhu, will relocate to Beijing, China, and lead these activities there. Dr. Zhu has over 20 years of industry experience in anti-viral and biologic drug development. Since she joined Brii Bio, she led the development of our SARS-CoV-2 neutralizing antibodies, amubarvimab and romlusevimab, and our HBV functional cure project, with great achievements in both projects,”  said Dr. Zhi Hong, Chairman and Chief Executive Officer of Brii Bio. “With rich experience in biomedical sciences, finance, law, and corporate development, Dr. Ankang Li has always been working closely with the Board on strategic planning. His joining the Board and serving as the chairman of the strategic committee will strengthen the governance by the Board. Mr. Rico Liang has worked in the hepatitis B and infectious disease field and collaborated with KOLs in China for many years. He also has extensive experience in commercialization of anti-infective therapeutics in China. As our new GM in China, Mr. Rico Liang will further build up our medical affairs, regulatory affairs, government affairs, commercial and local operations team in China. I want to thank Mr. Rogers Luo for his contribution to the company in the past two years and wish him success in his future endeavors.”

“Our R&D team in China has grown significantly in the past 4 years. They proved their capabilities through the success of our SARS-CoV-2 neutralizing antibody projects," said Dr. Qing Zhu. “I am excited to lead this first-class team to develop functional cure for HBV in China for the global chronic hepatitis B patients.”

“I am honored to join our very diverse Board consisting of industry experts and serve as the chair of the strategic committee,” said Dr. Ankang Li. “I look forward to further strengthening the communication between the Board and the management, and developing the strategy for company’s long-term success.”

“I will further build up our China team and improve operational excellence,” said Mr. Rico Liang. “By leveraging my experience in the field of HBV and infectious disease and actively collaborating with various stakeholders, I will support our R&D team to advance our pipeline programs, and lead our commercial team to ramp up our commercialization effort.”

“I am grateful for my two years at Brii Bio working with a world-class team and expanding my experience in drug development,” said Mr. Rogers Luo. “In the past two years, we have put patients first and successfully developed and commercially launched in China the first locally discovered neutralizing antibody therapy for COVID-19 despite numerous challenges. We also donated the antibodies to treat infected patients in many cities in China. These are memorable professional experiences and I am very proud of being part of the Brii Bio team.”

About Brii Bio

Brii Biosciences Limited (“Brii Bio”, stock code: 2137.HK) is a biotechnology company based in China and the United States committed to advancing therapies for significant infectious diseases, such as hepatitis B, COVID-19, human immunodeficiency virus (HIV) infection, multi-drug resistant (MDR) or extensive drug resistant (XDR) gram-negative infections, and other illnesses, such as the central nervous system (CNS) diseases, which have significant public health burdens in China and worldwide. For more information, visit www.briibio.com.

Media Inquiry:
Summer Li (China)
Darcie Robinson (U.S.)

Investor Inquiry:
Chris Fang